CY1122092T1 - Ιατρικη χρηση ανθρωπινων αντισωματων υψηλης συγγενειας κατα του ανθρωπινου υποδοχεα il-4 - Google Patents

Ιατρικη χρηση ανθρωπινων αντισωματων υψηλης συγγενειας κατα του ανθρωπινου υποδοχεα il-4

Info

Publication number
CY1122092T1
CY1122092T1 CY20181100734T CY181100734T CY1122092T1 CY 1122092 T1 CY1122092 T1 CY 1122092T1 CY 20181100734 T CY20181100734 T CY 20181100734T CY 181100734 T CY181100734 T CY 181100734T CY 1122092 T1 CY1122092 T1 CY 1122092T1
Authority
CY
Cyprus
Prior art keywords
human
receptor
high affinity
antibodies against
medical use
Prior art date
Application number
CY20181100734T
Other languages
English (en)
Inventor
Nicholas J. Papadopoulos
Jeanette L. Fairhurst
Tammy T. Huang
Joel H. Martin
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41600767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122092(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1122092T1 publication Critical patent/CY1122092T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Ένα αντίσωμα ή αντιγονοδεσμευτικό θραύσμα αυτού που δεσμεύει ειδικά τον ανθρώπινο υποδοχέα ιντερλευκίνης-4 (hlL-4R) (SEQ ID ΝΟ:274) με συγγένεια περίπου 300 pΜ ή μικρότερη.
CY20181100734T 2008-10-29 2018-07-16 Ιατρικη χρηση ανθρωπινων αντισωματων υψηλης συγγενειας κατα του ανθρωπινου υποδοχεα il-4 CY1122092T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12/260,307 US7608693B2 (en) 2006-10-02 2008-10-29 High affinity human antibodies to human IL-4 receptor
EP09744292.5A EP2356151B1 (en) 2008-10-29 2009-10-27 High affinity human antibodies to human il-4 receptor
EP13163791.0A EP2636685A1 (en) 2008-10-29 2009-10-27 High affinity human antibodies to human IL-4 receptor
EP12175412A EP2511300A3 (en) 2008-10-29 2009-10-27 High affinity human antibodies to human IL-4 receptor

Publications (1)

Publication Number Publication Date
CY1122092T1 true CY1122092T1 (el) 2020-07-31

Family

ID=41600767

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20131100565T CY1114123T1 (el) 2008-10-29 2013-07-05 Ανθρωπινα αντισωματα υψηλης συγγενειας εναντιον ανθρωπινου υποδοχεα il-4
CY2018003C CY2018003I2 (el) 2008-10-29 2018-01-17 Ανθρωπινα αντισωματα υψηλης συγγενειας εναντιον ανθρωπινου υποδοχεα il-4
CY20181100734T CY1122092T1 (el) 2008-10-29 2018-07-16 Ιατρικη χρηση ανθρωπινων αντισωματων υψηλης συγγενειας κατα του ανθρωπινου υποδοχεα il-4

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20131100565T CY1114123T1 (el) 2008-10-29 2013-07-05 Ανθρωπινα αντισωματα υψηλης συγγενειας εναντιον ανθρωπινου υποδοχεα il-4
CY2018003C CY2018003I2 (el) 2008-10-29 2018-01-17 Ανθρωπινα αντισωματα υψηλης συγγενειας εναντιον ανθρωπινου υποδοχεα il-4

Country Status (48)

Country Link
US (7) US7608693B2 (el)
EP (7) EP3715372B1 (el)
JP (8) JP5291802B2 (el)
KR (1) KR101599706B1 (el)
CN (3) CN102197052B (el)
AR (1) AR073978A1 (el)
AU (1) AU2009311496B9 (el)
BR (1) BRPI0919853B8 (el)
CA (1) CA2737044C (el)
CL (1) CL2009002004A1 (el)
CO (1) CO6362024A2 (el)
CR (1) CR20110148A (el)
CY (3) CY1114123T1 (el)
DK (3) DK2356151T3 (el)
EC (1) ECSP11011010A (el)
ES (3) ES2802241T3 (el)
FI (1) FI3715372T3 (el)
FR (1) FR18C1011I2 (el)
HK (2) HK1159136A1 (el)
HN (1) HN2011001210A (el)
HR (2) HRP20130467T1 (el)
HU (2) HUS1800014I1 (el)
IL (1) IL211726A (el)
JO (1) JO2865B1 (el)
LT (3) LT3715372T (el)
LU (1) LUC00059I2 (el)
MA (1) MA32802B1 (el)
MX (2) MX2011003346A (el)
MY (1) MY152448A (el)
NI (1) NI201100064A (el)
NL (1) NL300922I2 (el)
NO (2) NO2018009I2 (el)
NZ (2) NZ596093A (el)
PA (1) PA8847001A1 (el)
PE (1) PE20100738A1 (el)
PH (1) PH12014500462A1 (el)
PL (3) PL2356151T3 (el)
PT (4) PT3715372T (el)
RS (2) RS57522B1 (el)
RU (2) RU2539774C3 (el)
SI (2) SI3064511T1 (el)
SM (1) SMT201300074B (el)
SV (1) SV2011003880A (el)
TW (3) TWI658833B (el)
UA (1) UA102122C2 (el)
UY (1) UY32213A (el)
WO (1) WO2010053751A1 (el)
ZA (1) ZA201101867B (el)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763249B2 (en) * 2004-04-27 2010-07-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid β peptide antibody and fragment of said antibody
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
ME02646B (me) 2010-02-08 2017-06-20 Regeneron Pharma Miš sa zajedničkim lakim lancem
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
UA111731C2 (uk) * 2010-10-06 2016-06-10 Рідженерон Фармасьютікалз, Інк. Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
RU2721279C2 (ru) 2011-01-28 2020-05-18 Санофи Байотекнолоджи Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EP3865581A1 (en) 2011-08-05 2021-08-18 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
EP4252857A3 (en) 2011-09-16 2023-12-06 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
EA029290B1 (ru) * 2011-12-22 2018-03-30 Астеллас Фарма Инк. Новое антитело против ctgf человека
MY172730A (en) 2012-03-16 2019-12-11 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
US9801362B2 (en) 2012-03-16 2017-10-31 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
AR092177A1 (es) 2012-08-21 2015-03-25 Sanofi Sa Metodos para tratar o prevenir asma administrando un antagonista de il-4r
TWI721272B (zh) * 2012-08-21 2021-03-11 法商賽諾菲生物技術公司 投與il-4r拮抗劑以治療或預防氣喘之方法
PT2892927T (pt) * 2012-09-07 2018-08-02 Regeneron Pharma Métodos para tratamento da dermatite atópica por administração de um antagonista de il-4r
ES2675779T3 (es) 2012-09-07 2018-07-12 Regeneron Pharmaceuticals, Inc. Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20230066127A (ko) 2013-06-21 2023-05-12 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
SG10201912898XA (en) * 2013-06-21 2020-02-27 Sanofi Biotechnology Methods for treating nasal polyposis by administering an il-4r antagonist
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
EP3094644B1 (en) * 2014-01-16 2019-07-24 Mondelli, Mario Umberto Franceso Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
IL247290B (en) * 2014-02-21 2021-06-30 Sanofi Biotechnology Methods of treating or preventing asthma by adding an il-4r antagonist
KR20220029765A (ko) 2014-02-21 2022-03-08 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한 천식의 치료 또는 예방 방법
MX2016011132A (es) * 2014-02-28 2016-12-08 Regeneron Pharma Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
MX2016012274A (es) 2014-03-21 2017-05-23 Regeneron Pharma Animales no humanos que producen proteinas de union de dominio simple.
WO2016011256A1 (en) 2014-07-16 2016-01-21 Sanofi Biotechnology METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH)
KR20230158131A (ko) 2014-11-14 2023-11-17 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
JP6938383B2 (ja) * 2015-04-02 2021-09-22 インターベット インターナショナル ベー． フェー． イヌインターロイキン４受容体アルファに対する抗体
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
MX2018002000A (es) 2015-08-18 2018-06-19 Regeneron Pharma Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
CN109069625A (zh) 2016-02-19 2018-12-21 瑞泽恩制药公司 通过施用il-4r拮抗剂来增强疫苗功效的方法
CN113372446A (zh) * 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
KR102462039B1 (ko) 2016-09-01 2022-11-02 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
AU2017332732B2 (en) 2016-09-22 2024-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
US10925971B2 (en) 2016-11-29 2021-02-23 Regeneron Pharmaceuticals, Inc. Methods of treating PRLR positive breast cancer
TW202332696A (zh) 2016-12-01 2023-08-16 美商再生元醫藥公司 治療發炎症狀的方法
SG11201909457XA (en) 2017-04-13 2019-11-28 Regeneron Pharma Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
BR112020000127A2 (pt) 2017-07-06 2020-07-07 Regeneron Pharmaceuticals, Inc. método para selecionar um hidrolisado de soja, e, glicoproteína
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
MX2020004467A (es) 2017-10-30 2020-10-22 Sanofi Biotechnology Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CN115925882A (zh) 2017-12-22 2023-04-07 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
BR112020013336A2 (pt) 2018-01-31 2020-12-01 Regeneron Pharmaceuticals, Inc. produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário.
CN110105451B (zh) * 2018-02-01 2020-12-18 北京凯因科技股份有限公司 IL-4Rα抗体及其用途
KR102652133B1 (ko) * 2018-02-01 2024-03-29 베이징 카윈 테크놀로지 쉐어-홀딩 컴퍼니 리미티드 IL-4Rα 항체 및 그 용도
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
AU2019227531A1 (en) 2018-02-28 2020-10-15 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
US11054389B2 (en) 2018-03-19 2021-07-06 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US11332524B2 (en) 2018-03-22 2022-05-17 Surface Oncology, Inc. Anti-IL-27 antibodies and uses thereof
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
CN110540590B (zh) * 2018-05-29 2023-08-18 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制物的开发和应用
EA202190228A1 (ru) * 2018-07-10 2021-04-14 Ридженерон Фармасьютикалз, Инк. Модификация связывающих молекул для минимизации уже существующих взаимодействий
BR112021002989A2 (pt) * 2018-08-24 2021-05-11 Jiangsu Hengrui Medicine Co., Ltd. anticorpo para ligação de il-4r de humano, fragmento para ligação de antígeno e uso médico do mesmo
SG11202011970TA (en) 2018-08-27 2020-12-30 Regeneron Pharma Use of raman spectroscopy in downstream purification
TW202024639A (zh) 2018-08-30 2020-07-01 美商再生元醫藥公司 用於將蛋白質複合物定特徵之方法
CN110872349A (zh) 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
CN113166259A (zh) * 2018-11-09 2021-07-23 亚洲大学校产学协力团 对人IL-4受体α具有高亲和力的人抗体及其用途
US11312778B2 (en) 2018-11-21 2022-04-26 Brian C. Machler Method for treating allergic contact dermatitis
CN111518211B (zh) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
AU2020208396A1 (en) 2019-01-16 2021-05-20 Regeneron Pharmaceuticals, Inc. Methods for identifying free thiols in proteins
CN113677707A (zh) 2019-03-06 2021-11-19 瑞泽恩制药公司 用于在治疗癌症中增强效力的il-4/il-13途径抑制剂
EP3941589A1 (en) 2019-03-21 2022-01-26 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
WO2020231992A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
CN112010977B (zh) * 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 抗白介素4受体(il-4r)的抗体及其应用
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
BR112022000581A2 (pt) 2019-08-05 2022-03-03 Regeneron Pharma Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r
SG11202113310UA (en) 2019-08-05 2021-12-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
CA3150234C (en) 2019-09-24 2023-12-12 Robert Stairs Systems and methods for chromatography use and regeneration
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
EP4065086A1 (en) 2019-11-25 2022-10-05 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
BR112022011098A2 (pt) 2019-12-09 2022-09-20 Sanofi Biotechnology Métodos para tratamento de distúrbios relacionados a il-4/il-13 digitalmente identificados
MX2022008973A (es) 2020-01-21 2022-08-11 Regeneron Pharma Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
MX2022010217A (es) 2020-02-21 2022-09-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica que contiene anticuerpo anti-il-4r y uso de la misma.
US20230105029A1 (en) * 2020-02-27 2023-04-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibodies binding il4r and uses thereof
CN115427450A (zh) 2020-03-27 2022-12-02 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
BR112022022235A2 (pt) 2020-05-22 2023-03-28 Regeneron Pharma Métodos para tratamento de esofagite eosinofílica através da administração de inibidor de il-4r
WO2022047108A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
MX2023003942A (es) 2020-10-05 2023-06-02 Sanofi Biotechnology Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r.
JP2023551446A (ja) 2020-11-25 2023-12-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 非水膜乳化を使用した持続放出製剤
EP4262757A1 (en) 2020-12-17 2023-10-25 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
EP4269447A1 (en) 2020-12-22 2023-11-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof
EP4274609A1 (en) 2021-01-08 2023-11-15 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
KR20230134117A (ko) 2021-01-20 2023-09-20 리제너론 파마슈티칼스 인코포레이티드 세포 배양물에서 단백질 역가를 개선시키는 방법
KR20230150300A (ko) 2021-03-03 2023-10-30 리제너론 파마슈티칼스 인코포레이티드 단백질 점도를 정량화하고 변경시키기 위한 시스템 및 방법
BR112023018665A2 (pt) 2021-03-26 2023-10-03 Regeneron Pharma Métodos e sistemas para desenvolvimento de protocolos de mistura
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
AU2022316939A1 (en) 2021-07-26 2024-03-07 Regeneron Pharmaceuticals, Inc. Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
AR126749A1 (es) 2021-08-10 2023-11-08 Kymab Ltd Tratamiento de la dermatitis atópica
US20230167171A1 (en) 2021-08-23 2023-06-01 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
IL310427A (en) * 2021-08-26 2024-03-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pharmaceutical preparation of anti-R4IL antibody and use thereof
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
US20230151426A1 (en) 2021-09-30 2023-05-18 Regeneron Pharmaceuticals, Inc. Reticulocalbin-3 (RCN3) Variants And Treatment Of Asthma With Interleukin-4 Receptor Alpha (IL4R) Antagonists
AU2022359898A1 (en) 2021-10-07 2024-03-21 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
WO2023069976A1 (en) 2021-10-20 2023-04-27 Sanofi Biotechnology Methods for treating prurigo nodularis by administering an il-4r antagonist
US20230129265A1 (en) 2021-10-26 2023-04-27 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
WO2023085978A1 (en) * 2021-11-11 2023-05-19 Joint Stock Company «Biocad» Monoclonal antibody or antigen-binding fragment thereof that specifically binds to il-4ra, and use thereof
WO2023086887A1 (en) 2021-11-11 2023-05-19 Regeneron Pharmaceuticals, Inc. Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33)
WO2023091614A2 (en) * 2021-11-18 2023-05-25 Twist Bioscience Corporation Dickkopf-1 variant antibodies and methods of use
US20230272062A1 (en) 2021-11-30 2023-08-31 Regeneron Pharmaceuticals, Inc. Treatment Of Lung Disease Based Upon Stratification Of Polygenic Score Relating To Response To A Therapeutic Agent
WO2023130010A1 (en) 2021-12-30 2023-07-06 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
WO2023167871A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
WO2023177836A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2023191665A1 (en) * 2022-03-31 2023-10-05 Milaboratory, Limited Liability Company ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF
WO2024011251A1 (en) 2022-07-08 2024-01-11 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist
WO2024047021A1 (en) 2022-08-29 2024-03-07 Sanofi Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
KR20240038841A (ko) 2022-09-16 2024-03-26 연세대학교 산학협력단 신규한 인간 인터류킨-4 수용체 결합 나노바디 및 이의 용도

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
CA2108886A1 (en) * 1991-05-03 1992-11-04 Thasia G. Woodworth Interleukin receptor targeted molecules for treatment of inflammatory arthritis
SG52215A1 (en) * 1992-02-19 1998-09-28 Schering Corp Cloning and expresssion of humanized monoclonal antibodies against human interleukin-4
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) * 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US6387632B2 (en) * 1998-06-11 2002-05-14 Hitachi, Ltd. Polynucleotide separation method and apparatus therefor
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
ES2614260T3 (es) 2000-05-26 2017-05-30 Immunex Corporation Uso de anticuerpos contra el receptor de interleuquina-4 y composiciones de los mismos
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
EP1699825A2 (en) * 2003-12-22 2006-09-13 Amgen, Inc. Methods for identifying functional antibodies
JP2008504806A (ja) 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
AR050044A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
PT2374818E (pt) 2006-06-02 2013-02-13 Regeneron Pharma Anticorpos com elevada afinidade para o receptor il-6 humano
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PL2624865T3 (pl) * 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
AR092177A1 (es) * 2012-08-21 2015-03-25 Sanofi Sa Metodos para tratar o prevenir asma administrando un antagonista de il-4r
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20230066127A (ko) * 2013-06-21 2023-05-12 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
KR20220029765A (ko) * 2014-02-21 2022-03-08 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한 천식의 치료 또는 예방 방법
KR20230158131A (ko) * 2014-11-14 2023-11-17 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법

Also Published As

Publication number Publication date
IL211726A0 (en) 2011-06-30
EP2636685A1 (en) 2013-09-11
EP3715372B1 (en) 2024-01-24
PL3064511T3 (pl) 2018-09-28
FI3715372T3 (fi) 2024-03-18
US8337839B2 (en) 2012-12-25
JP2016041069A (ja) 2016-03-31
EP3351560A1 (en) 2018-07-25
RS52782B (en) 2013-10-31
TW201615216A (zh) 2016-05-01
FR18C1011I1 (el) 2018-04-27
EP2356151B1 (en) 2013-04-10
JP2020007378A (ja) 2020-01-16
US20120052072A1 (en) 2012-03-01
BRPI0919853A2 (pt) 2016-03-15
JP5844772B2 (ja) 2016-01-20
TW201029664A (en) 2010-08-16
RU2539774C2 (ru) 2015-01-27
CN102197052A (zh) 2011-09-21
HN2011001210A (es) 2013-10-22
PT3351560T (pt) 2020-05-11
ES2404206T3 (es) 2013-05-24
JP2012507294A (ja) 2012-03-29
EP3064511A1 (en) 2016-09-07
EP2511300A3 (en) 2012-11-07
HUE039212T2 (hu) 2018-12-28
JP6608505B2 (ja) 2019-11-20
CN106267190B (zh) 2021-01-26
CY1114123T1 (el) 2016-07-27
CN102197052B (zh) 2014-02-12
US8075887B2 (en) 2011-12-13
EP3351560B1 (en) 2020-04-22
ECSP11011010A (es) 2011-06-30
RU2014147773A (ru) 2016-06-20
EP2511300A2 (en) 2012-10-17
ES2802241T3 (es) 2021-01-18
ES2675917T3 (es) 2018-07-13
EP3064511B1 (en) 2018-04-18
LTPA2018002I1 (lt) 2018-02-12
CY2018003I1 (el) 2018-09-05
DK2356151T3 (da) 2013-06-17
RU2663106C2 (ru) 2018-08-01
JP6843208B2 (ja) 2021-03-17
RU2011120194A (ru) 2012-12-10
LT3064511T (lt) 2018-07-10
PT3064511T (pt) 2018-07-17
UA102122C2 (ru) 2013-06-10
CN103739711A (zh) 2014-04-23
JP7442581B2 (ja) 2024-03-04
FR18C1011I2 (fr) 2020-03-06
LT3715372T (lt) 2024-03-25
MX356882B (es) 2018-06-19
MA32802B1 (fr) 2011-11-01
AU2009311496B9 (en) 2014-10-30
PL2356151T3 (pl) 2013-08-30
EP2356151A1 (en) 2011-08-17
CA2737044A1 (en) 2010-05-14
RU2539774C3 (ru) 2020-11-06
LUC00059I2 (el) 2018-03-28
LUC00059I1 (el) 2018-01-03
TWI538686B (zh) 2016-06-21
UY32213A (es) 2010-05-31
JO2865B1 (en) 2015-03-15
US20130078675A1 (en) 2013-03-28
US8735095B2 (en) 2014-05-27
HK1159136A1 (en) 2012-07-27
CL2009002004A1 (es) 2010-03-05
US7608693B2 (en) 2009-10-27
DK3064511T3 (en) 2018-07-16
CO6362024A2 (es) 2012-01-20
SV2011003880A (es) 2011-08-15
JP6449125B2 (ja) 2019-01-09
LTC2356151I2 (lt) 2019-04-10
SMT201300074B (it) 2013-09-06
NI201100064A (es) 2011-11-02
US20140271681A1 (en) 2014-09-18
JP2013223495A (ja) 2013-10-31
IL211726A (en) 2015-10-29
TWI658833B (zh) 2019-05-11
PH12014500462A1 (en) 2015-06-01
DK3715372T3 (da) 2024-03-11
JP2024040526A (ja) 2024-03-25
CN103739711B (zh) 2016-09-14
EP3715372A1 (en) 2020-09-30
PT2356151E (pt) 2013-05-07
NO2023019I1 (no) 2023-05-02
NO2018009I2 (no) 2019-01-30
JP2021087440A (ja) 2021-06-10
NL300922I2 (nl) 2019-01-15
WO2010053751A1 (en) 2010-05-14
EP4345111A2 (en) 2024-04-03
JP7100731B2 (ja) 2022-07-13
BRPI0919853B1 (pt) 2020-10-27
US20090074793A1 (en) 2009-03-19
HRP20130467T1 (en) 2013-06-30
PT3715372T (pt) 2024-03-14
SI3064511T1 (en) 2018-08-31
HUS1800014I1 (hu) 2018-03-28
BRPI0919853B8 (pt) 2021-05-25
NO2018009I1 (no) 2018-03-06
HK1250733A1 (zh) 2019-01-11
KR20110074980A (ko) 2011-07-05
PA8847001A1 (es) 2010-05-26
CN106267190A (zh) 2017-01-04
AR073978A1 (es) 2010-12-15
US20180179288A1 (en) 2018-06-28
ZA201101867B (en) 2012-08-29
JP2022160404A (ja) 2022-10-19
AU2009311496B2 (en) 2014-05-29
NZ591922A (en) 2012-03-30
KR101599706B1 (ko) 2016-03-04
JP2019055963A (ja) 2019-04-11
US20210163611A1 (en) 2021-06-03
CA2737044C (en) 2017-02-28
MY152448A (en) 2014-09-30
MX2011003346A (es) 2011-04-21
AU2009311496A1 (en) 2010-05-14
RS57522B1 (sr) 2018-10-31
US20100047254A1 (en) 2010-02-25
PL3351560T3 (pl) 2020-09-21
SI2356151T1 (sl) 2013-07-31
TW201919700A (zh) 2019-06-01
CR20110148A (es) 2011-04-27
CY2018003I2 (el) 2018-09-05
NZ596093A (en) 2012-11-30
HRP20181148T1 (hr) 2018-09-21
PE20100738A1 (es) 2010-11-03
JP5291802B2 (ja) 2013-09-18

Similar Documents

Publication Publication Date Title
CY1122092T1 (el) Ιατρικη χρηση ανθρωπινων αντισωματων υψηλης συγγενειας κατα του ανθρωπινου υποδοχεα il-4
CY1115551T1 (el) Ανθρωπινα αντισωματα υψηλης συναφειας κατα του ανθρωπινου υποδοχεα il-4
UA111818C2 (uk) Антитіло проти csf-1r
CY1120144T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
CY1113087T1 (el) Ανθρωπινα αντισωματα εναντιον δελτα-παρομοιου προσδεματος 4
CY1124698T1 (el) Πρωτεϊνη δεσμευσης il-18 (il-18bp) σε φλεγμονωδεις νοσους
CU24058B1 (es) Antagonistas de pcsk9
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
DK2097453T3 (da) Monoklonale antistoffer mod humant Anti-Müllerian Hormon type II receptor (AMHR-II)
CR11298A (es) Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
CY1118710T1 (el) Συνθεσεις για την θεραπεια της πολλαπλης σκληρυνσης
CY1115437T1 (el) Υδροξυμεθυλοκυκλοεξυλαμινες
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
GB201021909D0 (en) Multi-analyte microarrays using tag-specific antibodies and tag-anchored antibodies
CY1117265T1 (el) Αντισωματα aνti-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
TN2011000133A1 (en) High affinity human antibodies to human il-4 receptor
UA97645C2 (ru) АНТИТЕЛО, СПЕЦИФИЧЕСКИ СВЯЗЫВАЮЩЕЕ РЕЦЕПТОР ИНТЕРЛЕЙКИНА-6 ЧЕЛОВЕКА (hIL-6R)
NZ757754A (en) Antibodies that bind csf1r
UA111322C2 (uk) Антитіло, що зв'язується переважно з позаклітинним доменом 4 людського csf-1r, і його застосування
TH95346A (th) แอนตี้-fgf 19 แอนตี้บอดี้และวิธีการใช้สิ่งเหล่านี้